Evidence map›Paper›PMID 30683080›Full record

ArticleBMC pulmonary medicine2019

A prospective study of salvational intervention with ICS/LABA for reducing chronic obstructive pulmonary disease exacerbation under severe air pollution (SIRCAP) in Beijing: protocol of a multi-center randomized controlled trial.

Tianyu Zhou, Yijue Zhong, Jiping Liao, Guangfa Wang, Xueying Li, Xiaosen Qian, Pingchao Xiang, Xinsheng Chen, Zhenyang Xu, Fengzhen Zhang and 7 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03083067 (A Prospective Study of Salvational Intervention With ICS/LABA for Reducing Chronic Obstructive Pulmonary Disease Exacerbation Under Severe Air Pollution), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03083067 nacompletednot on this map

A Prospective Study of Salvational Intervention With ICS/LABA for Reducing Chronic Obstructive Pulmonary Disease Exacerbation Under Severe Air Pollution (SIRCAP) in Beijing

TypeinterventionalSponsorPeking University First HospitalRan2017 to 2022Enrolled402ConditionsCOPD Exacerbation, Air PollutionArmsBudesonide/formoterol, tiotropium bromide
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tianyu ZhouDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Yijue ZhongDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Jiping LiaoDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Guangfa WangDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China. wangguangfa@hotmail.com.
Xueying LiDepartment of Medical Statistics, Peking University First Hospital, Beijing, China.
Xiaosen QianDepartment of Respiratory Medicine, Civil Aviation General Hospital, Beijing, China.
Pingchao XiangDepartment of Respiratory and Critical Care Medicine, Peking University Shougang hospital, Beijing, China.
Xinsheng ChenDepartment of Respiratory Medicine, The Hospital of Shunyi District Beijing, Beijing, China.
Zhenyang XuDepartment of Respiratory and Critical Care Medicine, Beijing Luhe Hospital capital medical university, Beijing, China.
Fengzhen ZhangDepartment of Respiratory Medicine, Aerospace 731 Hospital, Beijing, China.
Xiaoguang WangDepartment of Respiratory Medicine, Aerospace 731 Hospital, Beijing, China.
Senlin WangDepartment of Respiratory Medicine, Beijing Miyun Hospital, Beijing, China.
Xiangxin LiDepartment of Respiratory Medicine, Beijing Changping Hospital, Beijing, China.
Chunxiao YuDepartment of Respiratory Medicine, Beijing Jingmei Group General Hospital, Beijing, China.
Yongxiang ZhangDepartment of Respiratory Medicine, People's Hospital of Beijing Daxing District, Beijing, China.
Guoguang XiaDepartment of Respiratory and Critical Care Medicine, Beijing Jishuitan Hospital, Beijing, China.
Li DaiDepartment of Respiratory and Critical Care Medicine, Beijing Jishuitan Hospital, Beijing, China.

Funding

Capital Foundation of Medical Developments sponsored by Beijing Municipal Commission of Health and Family Planning SF2016-1-4071National key research and development plan sponsored by Ministry of science and technology of the People's Republic of China 2017YFC1309500
6 · The paper itself

Abstract

backgroundChronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality all over the world. Acute exacerbation of COPD (AECOPD) not only accelerates the progression of disease, but also causes hospital administration and death events. Epidemiologic studies have shown air pollution is a high risk factor of AECOPD. However, there are rare technics or treatment strategies recommended to reduce severe air pollution related AECOPD.

methodsThis is a multi-center, prospective, randomized and standard treatment parallel control clinical trial. Seven hundred sixty-four stable COPD patients in group B, C and D according to GOLD 2017 will be recruited and equally divided into two parallel groups, salvational intervention (SI group) and control group (CT group). Original treatments for participants include tiotropium (18μg once q.d), budesonide/formoterol (160μg/4.5μg once or twice b.i.d) or budesonide/formoterol (160μg/4.5μg once or twice b.i.d) with tiotropium (18μg once q.d). The savational intervention for SI group is routine treatment plus budesonide/formoterol (160μg/4.5μg once b.i.d) from the first day after severe air pollution (air quality index, AQI ≥200) to the third day after AQI < 200. CT group will maintain the original treatment. The intervention will last for 2 years. Primary outcome is the frequency of AECOPD per year and the secondary outcomes include the incidence of unplanned outpatient visits, emergency visits, hospitalization, medical cost and mortality associated with AECOPD per year. DISCUSSION: The salvational intervention is a novel strategy for COPD management under severe air pollution. Results of the present study will provide reference information to guide clinical practice in reducing the air pollution related exacerbation of COPD.

trial registrationThis study has been registered at www.ClinicalTrials.gov (registration identifier: NCT03083067 ) in 17 March, 2017.

Indexed as

Disease ProgressionAdultAgedAged, 80 and overAir PollutionBeijingBronchodilator AgentsBudesonideFemaleFormoterol FumarateHumansMaleMiddle AgedMulticenter Studies as TopicProspective StudiesPulmonary Disease, Chronic ObstructiveBronchodilator AgentsBudesonideFormoterol FumarateTiotropium BromideAECOPDAir pollutionBudesonide/FormoterolCOPDSalvational intervention

Identifiers

PMID30683080
PMCPMC6347780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.